Comprehensive Genomic Analysis for Identifying FZD6 as a Novel Diagnostic Biomarker for Acute Myeloid Leukemia

Table 2

Cox proportional hazards model for OS and PFS in AML patients.

Variables	OS		PFS
	HR (95% CI)		HR (95% CI)
Age	1.018 (1.001-1.035)	0.040	1.008 (0.991-1.026)	0.335
Sex (male vs. female)	0.811 (0.547-1.203)	0.298	0.752 (0.480-1.177)	0.212
WBC counts	1.007 (1.002-1.011)	0.002	1.007 (1.002-1.011)	0.006
BM blasts percentage	1.009 (0.998-1.020)	0.127	1.002 (0.989-1.016)	0.769
ELN risk stratification		0.006		0.018
(intermediate/adverse vs. favorable)	2.720 (1.341-5.518)		2.521 (1.173-5.419)
Induction therapy		0.001		0.474
(intensive vs. nonintensive)	0.371 (0.211-0.654)		0.736 (0.318-1.702)
HSCT (yes vs. no)	0.508 (0.304-0.848)	0.010	1.149 (0.644-2.052)	0.637
FZD6 expression	1.264 (1.025-1.559)	0.028	1.081 (0.853-1.370)	0.518

Abbreviations: OS, overall survival; PFS, progression free survival; HR, hazard ratio; CI, confidence interval.